MGD-22
MGD-22, a molecular glue, is an orally active IKZF1/2/3 degrader with DC50 values of 8.33 nM, 9.91 nM, and 5.74 nM, respectively. MGD-22 exhibits extremely potent anti-proliferative activity against diverse hematological cancer cells. MGD-22 induces apoptosis in cancer cells. MGD-22 demonstrates potent anti-tumor efficacy in mice bearing NCI-H929 xenografts or WSU-DLCL-2 xenografts. MGD-22 can be used for the study of hematological cancers, including multiple myeloma (MM), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL).
For research use only. We do not sell to patients.
- CAS No.: 2991818-12-1
- Formula: C33H35N7O3
- Molecular Weight:577.68
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
IKZF1 8.33 nM (DC50) |
IKZF2 9.91 nM (DC50) |
IKZF3 5.74 nM (DC50) |
In Vitro
MGD-22 (0-100 μM, 96 h) exhibits extremely potent anti-proliferative activity against multiple myeloma (MM) cell lines including NCI-H929 (IC50 = 7.93 nM), RPMI-8226 (IC50 = 83.2 nM), OPM-2 (IC50 = 7.87 nM); acute myeloid leukemia (AML) cell lines including MV-4-11 (IC50 = 5.38±0.43 nM), U937 (IC50 = 15.1 nM), MOLM-13 (IC50 = 196 nM), KG-1 (IC50 = 78.9 nM), Skm-1 (IC50 = 218 nM), MUTZ-1 (IC50 = 148 nM); diffuse large B-cell lymphoma (DLBCL) cell lines including WSU-DLCL-2 (IC50 = 8.99 nM), Ocl-Ly3 (IC50 = 95.3 nM), SU-DHL-4 (IC50 = 452 nM), TMD8 (IC50 = 87.7 nM), U2932 (IC50 = 8.17 nM); while showing negligible activity against normal peripheral blood mononuclear cells (PBMCs) and primary B cells (IC50 > 33 μM[1].
MGD-22 (0.01-10 μM, 72 h) induces dose-dependent apoptosis in NCI-H929 and MV-4-11 cells[1].
MGD-22 (0.001-1000 nM, 24 h) selectively induces robust degradation of IKZF1/2/3 in HEK293T cells engineered with IKZF1/2/3-HiBit tags, with DC50 values of 8.33 nM (IKZF1), 9.91 nM (IKZF2), and 5.74 nM (IKZF3), and maximal degradation (Dmax) of 94.33%, 91.58%, and 92.26% respectively[1].
MGD-22 (1 μM, 24 h) promotes the formation of a ternary complex between IKZF1/2/3 and CRBN in NCI-H929 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:NCI-H929 and MV-4-11 cells
-
Concentration:0.01, 0.1, 1, 10 μM
-
Incubation Time:72 h
-
Result:Induced dose-dependent apoptosis in NCI-H929 and MV-4-11 cells.
In Vivo
MGD-22 (5 mg/kg, p.o., once daily, 36 days) combined with Ibrutinib (HY-10997) or Venetoclax (HY-15531) for 36 days exhibits synergistic anti-tumor efficacy in NOD/SCID mice bearing WSU-DLCL-2 xenografts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NCI-H929 cells (7.5 × 106) were subcutaneously inoculated into both sides of the dorsal back of 6-week-old NOD/SCID mice to establish the multiple myeloma (MM) xenograft model[1]
-
Dosage:3, 10 mg/kg
-
Administration:p.o., once daily, 14 days
-
Result:Exhibited superior anti-tumor efficacy.
Caused only minor body weight reduction throughout the treatment period.
Reduced Ki67-positive proliferative cells and increases cleaved-caspase-3-positive apoptotic cells.
Degraded IKZF1/2/3 proteins in NCI-H929 xenograft tumor tissues.
-
Animal Model:WSU-DLCL-2 cells (1 × 107) were subcutaneously implanted into both sides of the dorsal back of 6-week-old NOD/SCID mice to construct the diffuse large B-cell lymphoma (DLBCL) xenograft model[1]
-
Dosage:5 mg/kg combined with Ibrutinib (HY-10997) (10 mg/kg, p.o., once daily) or Venetoclax (HY-15531) (30 mg/kg, p.o., once daily)
-
Administration:p.o., once daily, 36 days
-
Result:Demonstrated anti-tumor efficacy in NOD/SCID mice bearing WSU-DLCL-2 xenografts.
Improved the survival rate of NOD/SCID mice.
Maintained stable body weight.
Chemical Information
-
CAS No. 2991818-12-1
-
Molecular Weight 577.68
-
Formula C33H35N7O3
-
SMILES
O=C(N1)C(N2N(CC3=C(C=CC=C3C2=O)NCC4=CC=C(CN5CCN(CC5)C6=CC=C(C=C6)C#N)C=C4)C)CCC1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)